S. Ozakbas Et Al. , "Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study," Journal of Health Policy and Outcomes Research , vol.2024, no.1, pp.41-49, 2024
Ozakbas, S. Et Al. 2024. Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study. Journal of Health Policy and Outcomes Research , vol.2024, no.1 , 41-49.
Ozakbas, S., Baba, C., Yavas, I., SAMADZADE, U., & ÖZDOĞAR, A. T., (2024). Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study. Journal of Health Policy and Outcomes Research , vol.2024, no.1, 41-49.
Ozakbas, SERKAN Et Al. "Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study," Journal of Health Policy and Outcomes Research , vol.2024, no.1, 41-49, 2024
Ozakbas, SERKAN Et Al. "Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study." Journal of Health Policy and Outcomes Research , vol.2024, no.1, pp.41-49, 2024
Ozakbas, S. Et Al. (2024) . "Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study." Journal of Health Policy and Outcomes Research , vol.2024, no.1, pp.41-49.
@article{article, author={SERKAN ÖZAKBAŞ Et Al. }, title={Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? A large cohort study}, journal={Journal of Health Policy and Outcomes Research}, year=2024, pages={41-49} }